Khavinson BioregulatorTarget: EyeVisual

Pinalex

Pinalex Tab · Пиналекс · ocular peptide tablet

Pinalex is a commercial eye tablet that mixes ocular peptides with antioxidant cofactors (lutein, astaxanthin, and related label items). It is not Retinalamin, not Normoftal, and not a Cytomed Cytomax.

Not FDA-approved - research chemical

Quick answer

What it is: Pinalex is a commercial eye tablet that mixes ocular peptides with antioxidant cofactors (lutein, astaxanthin, and related label items).

Class and target: Stability analog (not a Khavinson original) · Eye (commercial tablet blend)

Typical research dose: Vendor tablet course (oral)

Dosing details ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team
Last updated: August 2026Evidence: Low1 peer-reviewed citation
Typical research dose
Vendor tablet course (oral)
Frequency
Per label
Half-life
Tablet blend (not a single PK)
Common vials
N/A (oral)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Injury & tissue1.5/10

    Commercial eye tablet blend with carotenoid cofactors. Not Retinalamin. Not AREDS. Identity only.

Compound card

Class
Commercial ocular tablet blend (not Retinalamin, not Visoluten)
Status
Not FDA-approved · research use

How it works

Pinalex is a commercial ocular tablet blend (peptide fraction plus antioxidant cofactors on typical labels). The Khavinson ocular map is Visoluten (oral Cytomax), Normoftal (cytogen), and Retinalamin (injectable extract).

Source: Vendor labels; Khavinson ocular class PMID 11713572

Khavinson map

Adjacent (not padded into the 41)
Class
Stability analog (not a Khavinson original)
Organ
Eye (commercial tablet blend)
Target
Eye
System
Visual
Sequence
Mixture / not a single CAS
Pair
Visoluten (ocular Cytomax)
Пиналекс

Used in bioregulator stacks

Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.

The Khavinson school

Pinalex is filed here as stability analog (not a khavinson original), targeting the eye (commercial tablet blend). Khavinson's St. Petersburg group moved from organ extracts (Cytamins) to capsule complexes (Cytomaxes) to synthetic short peptides (Cytogens); most of the evidence comes from that one group, with little independent Western replication.

Read the full background, the proposed epigenetic mechanism, the literature limits, and how we count the canonical 41 on the Khavinson bioregulators index.

History of this molecule

English stack pages drop “Pinalex” into the vision protocol next to Visoluten. Vendor labels describe a tablet for visual fatigue and age-related acuity, often combining a peptide fraction with carotenoids.

That is a nutraceutical blend, not a Khavinson sequence paper. The Khavinson ocular map is three products: Visoluten (oral extract), Normoftal (cytogen), Retinalamin (injectable extract). Pinalex sits beside that map as a later SKU.

We add the leaf so /stacks/vision is not a dead end, then we send readers to the three actual Khavinson ocular identities.

Caveats

Not a glaucoma drug, not an AMD indication, not an eye drop. Carotenoid doses on a label do not make the peptide fraction evidence-based.

Full 41-map: Khavinson bioregulators index · Bioregulator stacks

Research Use Cases

  • ✓Catalog identity: Low

Dosing

PhaseDoseFrequencyNotes
Vendor tabletPer labelOralNot parabulbar Retinalamin.

Administration

Route / form
Swallowed tablets. Not a Cytomed Cytomax, not a sublingual melt, and not a reconstitution vial.
Timing
Morning, with water, about 30 minutes before meals (empty stomach).
Empty stomach?
Yes - Empty stomach - about 30 minutes before meals. Cytomed boxes sometimes print “with food” because they are labeled as supplements; the manufacturer user-guide preference is before meals for absorption.

Pinalex: Swallowed tablet blend vs Not Retinalamin

Swallowed tablet blend
Bioavailability
Swallowed tablets with water. Not a Cytomed Cytomax, not Normoftal cytogen, not a sublingual melt. Blend: ocular peptide fraction plus lutein/astaxanthin-class cofactors on typical vendor labels.
Dose note
Follow the tablet insert. No mg/mL. If the goal is the Khavinson ocular triad, start at Visoluten / Normoftal / Retinalamin.
Advantages
  • This is the actual SKU: a tablet. Oral column is the product.
  • Searchable name so vision stacks are not a dead end.
  • Not a sublingual tablet. Nobody manufactures this SKU that way.
Considerations
  • Not in the 41. Analog/adjacent commercial blend.
  • Do not launder AREDS or Retinalamin onto this bottle.
  • Not a glaucoma or AMD drug.
Not Retinalamin
Bioavailability
Pinalex is a swallowed commercial eye tablet (peptide fraction plus antioxidant cofactors on typical labels). It is not Retinalamin. There is no reconstitution step and no parabulbar presentation.
Dose note
Do not invent IM or parabulbar math. If the plan is CIS injectable retina extract, that is the Retinalamin leaf. If the plan is Cytomed ocular Cytomax, that is Visoluten.
Advantages
  • Keeps a later blend from stealing Retinalamin’s hospital route.
  • Tablets do not go in the reconstitution calculator (empty rows are correct).
  • Not an eye drop.
Considerations
  • Not a Khavinson original sequence paper.
  • Carotenoid label items are not AREDS2 and not Retinalamin series.
  • Gray-market “Pinalex vials” would be a different, dishonest SKU.
Recommendation: Pinalex is a swallowed eye tablet blend, not in the 41. It is not Retinalamin (parabulbar/IM extract), not Visoluten (ocular Cytomax capsules), not Normoftal (retina cytogen), and not a sublingual tablet. No reconstitution. No fake extract chart.

Timeline

Label folklore
Visual-fatigue marketing - not an AMD indication.

Who it is for

Catalog identity

Low

Named on vision stacks. Route to Visoluten / Normoftal / Retinalamin for the Khavinson line.

Safety & Considerations

Not a glaucoma or AMD drug. Carotenoid cofactors are a different evidence body than Khavinson retinal peptides.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Do not launder AREDS or Retinalamin onto this SKU.

Verdict

Pinalex is a later eye tablet blend. The Khavinson ocular map is Visoluten, Normoftal, and Retinalamin. Not AREDS-2.

Interactions & Contraindications

Not a glaucoma or AMD drug. Carotenoid cofactors are a different evidence body than Khavinson retinal peptides.

Frequently Asked Questions

Is Pinalex Visoluten?▼
No. Visoluten is the Cytomed ocular Cytomax. Pinalex is a later tablet blend that may include ocular peptides plus antioxidants.
Why is it on the stacks hub?▼
Eye protocols name it. We keep the name so search works, then we route to Visoluten, Cerluten, and Ventfort as the Khavinson leaves in that stack.

References

  1. Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2001). PMID: 11713572

📚 Related Articles

Khavinson Bioregulators: Vilon, Thymalin, Cortexin & the Russian Peptide Legacy
14 min read • Longevity

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →
← Back to Peptide Library·Bioregulator stacks